Gastro-intestinale tumoren
- PROTECT: PROton versus photon Therapy for Esophageal Cancer – a Trimodality strategy
Contact: prof. dr. K. Haustermans
Hersentumoren
- NARCiS: Neurocognition after radiotherapy in adult brain and base of skull tumours
Contact: prof. dr. M. Lambrecht - LEGATO: Lomustine with or without reirradiation for first progression of glioblastoma: a randomized phase III study
Contact: prof.dr. M. Lambrecht
Hoofd- en halstumoren
- NANORAY-312: A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator’s Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma
Contact: prof. dr. S. Nuyts
Longtumoren
- LAT-FLOSI: Local ablative therapy for oligoprogressive non-small-cell lung cancer treated with first-line osimertinib.
Contact: dr. P. Berkovic
Niet-ziekte specifieke studies
- LAT-MUM: Local ablative therapy for patients with multiple (4-10) brain metastases.
Contact: dr. P. Berkovic
Prostaattumoren
- PART: Elective para-aortic radiotherapy (PART) for pN1 prostate cancer: a phase 2 trial using Arc therapy (IMAT / VMAT).
Contact: prof. dr. G. De Meerleer - OBELIX: Observational study on extreme hypofractionation for localized prostate cancer.
Contact: prof. dr. G. De Meerleer - SPARKLE: Metastasis-directed therapy for oligocurrent prostate cancer: a randomized phase III trial.
Contact: prof. dr. G. De Meerleer - MEDCARE: Metastasis-directed therapy in oligoprogressive castration-refractory prostate cancer: a randomized phase 3 trial
Contact: prof. dr. G. De Meerleer - HYPOFLAME 3.0: Standard moderately hypofractionated radiotherapy vs. ultra-hypofractionated focal lesion ablative microboost in prostate cancer
Contact: Prof.dr. K. Haustermans - STEREOBED: coming soon
Contact: prof. C. Berghen
Gerelateerd
Laatste aanpassing:
13 augustus 2025